A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer

Nature Communications
Xiujuan WuYi Zhang

Abstract

Currently, one sixth of triple-negative breast cancer (TNBC) patients who receive docetaxel (T) and epirubicin (E) as neoadjuvant chemotherapy achieve a pathologic complete response (pCR). This study evaluates the impact of adding lobaplatin (L) to the TE regimen. Here, we show data from 125 patients (63 TE and 62 TEL patients). Four patients did not complete all the cycles. Two-sided P values show that the addition of L (38.7% vs. 12.7%, P = 0.001) significantly increases the rate of pCR in the breast and the axilla (TpCR) and the overall response rate (ORR; 93.5% vs. 73.0%, P = 0.003). The occurrence of grade 3-4 anemia and thrombocytopenia is higher in the TEL group (52.5% vs. 10.0% and 34.4% vs. 1.7% respectively). These results demonstrate that the addition of L to the TE regimen as neoadjuvant chemotherapy improves the TpCR and the ORR rates of TNBC but with increased side effects.

References

Apr 13, 2006·JAMA : the Journal of the American Medical Association·Donald A BerryEric P Winer
Oct 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vernon HarveySoeren Cold
May 22, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Günther G StegerRaimund Jakesz
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca DentSteven A Narod
Feb 6, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cornelia LiedtkeLajos Pusztai
Jan 21, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P BonoH Joensuu
Feb 17, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G FrasciG D'Aiuto
Jan 27, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel P SilverJudy E Garber
Feb 19, 2010·The Cancer Journal·Steven J Isakoff
Jul 2, 2010·Cancer Chemotherapy and Pharmacology·Hiroko MasudaToshimasa Tsujinaka
Dec 29, 2010·Breast Cancer Research and Treatment·Nicholas J RobertJoyce A O'Shaughnessy
Jan 21, 2012·The Breast : Official Journal of the European Society of Mastology·Mustafa KhasrawChau Dang
Apr 18, 2013·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Yi YinXiao-Zhou Xu
Nov 19, 2013·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Xiaoqin LiDonghong Wang
Dec 19, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G G StegerUNKNOWN Austrian Breast and Colorectal Study Group (ABCSG)
Feb 27, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Nan WangJia-Rui Li
Oct 29, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joyce O'ShaughnessyEric P Winer

❮ Previous
Next ❯

Citations

Jul 14, 2020·The Breast Journal·Hirotaka MiyashitaStephen C Malamud
Jun 21, 2019·Dose-response : a Publication of International Hormesis Society·Hongwen CaoChao Yu
Apr 16, 2021·Chemistry : a European Journal·Nazia Nayeem, Maria Contel
Mar 30, 2019·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Jingchao He, Haijun Zhang
Aug 1, 2021·The FEBS Journal·Nataša Pavlović, Femke Heindryckx

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
biopsies
X-ray

Software Mentioned

SPSS
Research Randomizer

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.